SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by BridgeBio Pharma, Inc. and its officers or directors [1] Group 1: Company Developments - On June 4, 2024, BridgeBio announced positive results from the PROPEL 2 Phase 2 trial of infigratinib for children with achondroplasia, highlighting its potential best-in-class efficacy and safety profile [2] - Despite the positive trial results, an analyst from Pipe Sandler expressed concerns that infigratinib does not significantly differentiate from BioMarin's Voxzogo, indicating a mixed competitive threat [2] - Following the announcement, BridgeBio's stock price decreased by $1.85, or 6.38%, closing at $27.13 per share on June 4, 2024 [2] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3] - The firm has successfully recovered numerous multimillion-dollar damages awards for class members over its 80-year history [3]